WASHINGTON, Aug. 15, 2017 /PRNewswire/ -- The
Antimicrobials Working Group (AWG) announced today the addition of
two new members to their group of 12 companies with the mission to
combat drug resistant infections and spur life-saving innovations.
T2 Biosystems, Inc. (NASDAQ:TTOO), is an emerging leader in the
development of innovative diagnostic products to improve patient
health, and is AWG's first diagnostic member company. Aridis
Pharmaceuticals, Inc. is a biopharmaceutical company applying
proprietary technologies to produce novel immunotherapeutics for
infectious diseases.
"Diagnostics play a vital role in providing the best possible
patient care and combatting the global health threat of
antimicrobial resistance," said Jeffrey Stein, Ph.D.,
president and chief executive officer of Cidara Therapeutics and
Chairman of the AWG. "T2 Biosystems is a leading innovator in the
field and their T2MR detection technology enables the delivery of
life-saving medicines more rapidly to patients and reduces the use
of unnecessary drug exposure. We're excited to have their expertise
in the fight against superbugs and drug resistant infections. In
addition, I believe that immunotherapeutics, such as those being
developed by Aridis, represent the wave of the future and will
become an increasingly important source of potent, highly selective
treatments in our antimicrobial armamentarium."
"T2 is proud to become the first diagnostic company member of
the AWG," said John McDonough,
President & CEO of T2 Biosystems. "We look forward to adding
our voice along with the rest of the AWG membership to help improve
the regulatory, investment and commercial environment for emerging
companies."
Vu Truong, Ph.D., Founder and CEO
of Aridis said: "We welcome the opportunity to work with the AWG
membership, regulators and policymakers to help revitalize the
pipeline of new antimicrobial drugs. The AWG has been very
influential in their work to date and we are excited to contribute
to these critically important efforts."
About T2 Biosystems
T2 Biosystems is dedicated to developing innovative diagnostic
products to improve patient health. With the FDA-cleared T2Dx®
Instrument and T2Candida® Panel targeting sepsis and a range of
additional products in development, T2 Biosystems is an emerging
leader in the field of in vitro diagnostics. The Company is
utilizing its proprietary T2 Magnetic Resonance technology, or
T2MR, to develop a broad set of applications aimed at lowering
mortality rates, improving patient outcomes and reducing the cost
of healthcare by helping medical professionals make targeted
treatment decisions earlier. T2MR enables the fast and sensitive
detection of pathogens, biomarkers and other abnormalities in a
variety of patient sample types, including whole blood. For more
information, please visit www.t2biosystems.com.
About Aridis Pharmaceuticals, Inc.
Aridis is a privately held biopharmaceutical company applying
proprietary monoclonal antibody discovery technology MabIgX® to
produce novel infectious disease focused therapies. Aridis' product
pipeline includes AR-101 (or 'Aerumab™') anti-Pseudomonas
aeruginosa LPS human monoclonal antibody; AR-301 (or 'Salvecin®')
anti-Staphylococcus aureus human monoclonal antibody to treat acute
pneumonia; Aerucin®, a broadly reactive monoclonal antibody against
Pseudomonas aeruginosa initially being developed to treat acute
pneumonia; Panaecin™, a small molecule anti-infective gallium
compound with broad spectrum activities against bacteria, viruses,
and fungi; AR- 401 anti-Acinetobacter baumannii human monoclonal
antibody; and AR-201 anti-RSV human monoclonal antibody.
About The Antimicrobials Working Group
AWG was founded in 2012 with the vision of utilizing collective
power to improve the regulatory, investment, and commercial
environment for emerging antibiotics and antifungal companies.
Today, AWG is comprised of fourteen antimicrobials and diagnostics
companies: Amplyx Pharmaceuticals, Aridis Pharmaceuticals, Arsanis
Inc., Cidara Therapeutics Inc., ContraFect Corporation, Iterum
Therapeutics Ltd., Melinta Therapeutics Inc., Nabriva Therapeutics
US Inc., Paratek Pharmaceuticals Inc., SCYNEXIS Inc., T2 Biosystems
Inc., Theravance Biopharma U.S. Inc., Viamet Pharmaceuticals Inc.,
and Zavante Therapeutics Inc. For more information, please visit
www.antimicrobialsworkinggroup.org.
About The Conafay Group
The Conafay Group is a life-sciences government relations firm
based in Washington D.C. that
serves as Washington counsel and
coalition manager for AWG, led by Stephen
R. Conafay, Principal. For more information, please visit
www.conafaygroup.com.
View original
content:http://www.prnewswire.com/news-releases/t2-biosystems-and-aridis-pharmaceuticals-inc-join-antimicrobials-working-group-300504514.html
SOURCE Antimicrobials Working Group (AWG)